IDO1 and neoplasm: These observations have provided a rationale for developing immunotherapy strategies that interfere with these immune suppressive pathways toward restoring T cell function at the tumor site, including monoclonal antibodies blocking PD-L1/PD-1 interactions and small molecule inhibitors of IDO.